Newron Pharmaceuticals SpA in Bresso

Firmenprofil Newron Pharmaceuticals SpA im Branchenportal Medical.ch

Newron Pharmaceuticals SpA
Via Ludovico Ariosto 21
20091 Bresso
Italien
Tel.: +39 02 610 3461
Fax: +39 02 610 34654

Das Unternehmen kontaktieren

Weitere Informationen

Werben mit Medical.ch »

HELP Award 2024

mehr Infos über das Bewertungssystem

Kundenmeinungen
Newron Pharmaceuticals SpA für den HELP Award 2024 bewerten

Jetzt Newron Pharmaceuticals SpA bewerten

Werben mit Medical.ch »

Standorte

Weitere Infos, Map

Werben mit Medical.ch »

✔HELPads

Beschreibung und Mehrwerte

Pharmaceuticals

Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on novel therapies for diseases of the Central Nervous System and pain. Newron is undertaking phase III trials with safinamide for the treatment of Parkinson’s disease (PD) in conjunction with its partner, Merck Serono, which has exclusive worldwide rights to develop, manufacture and commercialize the compound in PD, Alzheimer´s disease, and other therapeutic applications.

Newron recently reported excellent results for its compound ralfinamide in patients with Nerve Compression and Entrapment conditions, of which neuropathic low back pain (NLBP) represents the most common indication. There are no approved drugs for NLBP. The company expects to commence a phase IIb/III in NLBP later in 2008. In May 2008, Newron acquired Hunter-Fleming, a private UK bio-pharmaceutical company developing new medicines to treat neurodegenerative and inflammatory disorders.

Newron is headquartered in Bresso, near Milan, Italy. The company is listed at SWX Swiss Exchange, trading symbol NWRN.

Sehen Sie hier das Unternehmens-Firmenprofil von Newron Pharmaceuticals SpA in Bresso. Dieses Firmenporträt hat die ID HLP-35-223781.